Temporomandibular dysfunction (TMD) covers two broad pain categories that require different management. Myofascial TMD pain originates in the muscles of mastication (masseter, temporalis, medial and lateral pterygoid) and presents as diffuse jaw ache, temple pressure, tender muscle bellies on palpation, and pain worsened by clenching or chewing. Arthrogenous (joint) TMD originates in the TMJ itself and presents as joint click with deviation, joint pain on opening or closing, locking, or structural disc displacement, often confirmed on imaging. Distinguishing the two on examination is the critical differential decision — myofascial pain responds to muscle-directed botulinum toxin therapy combined with physical therapy and NSAID; arthrogenous pain with structural pathology generally needs referral to a TMD specialist for splint, arthroscopy or other targeted intervention before muscle-directed Botox.
For patients with predominantly myofascial TMD pain, randomized and observational evidence (J Oral Rehabil 2020, DOI: 10.1111/joor.13073; J Headache Pain 2020, DOI: 10.1186/s10194-020-01115-4) supports botulinum toxin type A injection into the masseter (30 to 50 units per side) and temporalis (15 to 25 units per side at 2 to 3 points per side) for myofascial pain intensity reduction, masseter tenderness reduction and chewing-related pain improvement. In selected cases with lateral pterygoid involvement contributing to closed-lock symptoms an experienced injector may add lateral pterygoid (10 to 15 units per side) under careful anatomic guidance, though this is an advanced step reserved for established TMD specialists. The combined dose distribution distinguishes TMJ Pain Botox from the narrower functional bruxism protocol (masseter only) and from aesthetic jaw slimming (masseter only at higher dose).
At Kind Global Clinic Myeongdong, both co-directors personally administer TMJ Pain Botox — there is no nurse delegation, no junior-doctor rotation. Consultation includes a structured TMD differential: muscle palpation of masseter, temporalis, medial pterygoid, and lateral pterygoid (intraoral access); joint exam for click, lock, deviation and structural pathology; review of imaging when available (panoramic, MRI for joint structure); and screen for red-flag features (trauma, infection, neoplasm) that require non-Botox workup. Brand, lot number, exact unit count per muscle per side and the patient's TMD baseline pain scores are recorded on the patient chart. The 4 to 6 month re-treatment interval is standard; physical therapy and NSAID coordination continues throughout.